Discounted Cash Flow
Urogen Pharma Ltd.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $17.5m | $-1.9m | $3.5m | -11.1% | $-1.91 |
| 2017 | $8.2m (-53.5%) | $-20.0m (-930.4%) | $-9.8m (-381.7%) | -245.2% (-2114.1%) | $-2.14 (-12.0%) |
| 2018 | $1.1m (-86.2%) | $-75.7m (-278.3%) | $-37.9m (-285.0%) | -6707.2% (-2635.9%) | — |
| 2019 | $18.0k (-98.4%) | $-105.1m (-39.0%) | $-71.3m (-88.3%) | -584144.4% (-8609.2%) | — |
| 2020 | $11.8m (65450.0%) | $-128.5m (-22.2%) | $-107.1m (-50.1%) | -1088.9% (99.8%) | — |
| 2021 | $48.0m (307.2%) | $-110.8m (13.7%) | $-85.6m (20.0%) | -230.7% (78.8%) | — |
| 2022 | $64.4m (34.0%) | $-109.8m (0.9%) | $-87.8m (-2.5%) | -170.6% (26.0%) | $-4.81 |
| 2023 | $82.7m (28.5%) | $-102.2m (6.9%) | $-76.6m (12.8%) | -123.6% (27.5%) | $-3.55 (26.2%) |
| 2024 | $90.4m (9.3%) | $-126.9m (-24.1%) | $-97.1m (-26.8%) | -140.4% (-13.5%) | $-2.96 (16.6%) |
| 2025 | $109.8m (21.4%) | $-153.5m (-21.0%) | $-162.7m (-67.7%) | -139.8% (0.4%) | $-3.19 (-7.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.